Credit Industriel ET Commercial Sells 26,300 Shares of Surmodics, Inc. $SRDX

Credit Industriel ET Commercial trimmed its position in Surmodics, Inc. (NASDAQ:SRDX) by 30.8% in the 2nd quarter, Holdings Channel reports. The firm owned 59,200 shares of the company’s stock after selling 26,300 shares during the quarter. Credit Industriel ET Commercial’s holdings in Surmodics were worth $1,759,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of SRDX. Strs Ohio bought a new position in Surmodics in the 1st quarter valued at $122,000. AlphaQuest LLC bought a new position in Surmodics in the 1st quarter valued at $232,000. Inspire Investing LLC boosted its holdings in Surmodics by 11.3% in the 1st quarter. Inspire Investing LLC now owns 11,250 shares of the company’s stock valued at $343,000 after purchasing an additional 1,142 shares during the period. Invesco Ltd. boosted its holdings in Surmodics by 103.9% in the 1st quarter. Invesco Ltd. now owns 11,844 shares of the company’s stock valued at $362,000 after purchasing an additional 6,036 shares during the period. Finally, Maven Securities LTD bought a new position in Surmodics in the 1st quarter valued at $366,000. 96.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SRDX has been the subject of several analyst reports. Barrington Research reissued a “market perform” rating on shares of Surmodics in a report on Monday, August 11th. Zacks Research raised shares of Surmodics to a “hold” rating in a report on Tuesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surmodics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $43.00.

Surmodics Stock Performance

Surmodics stock opened at $27.92 on Tuesday. The firm’s fifty day moving average price is $33.05 and its 200-day moving average price is $30.90. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.10 and a current ratio of 3.91. The stock has a market cap of $399.26 million, a P/E ratio of -22.70 and a beta of 1.31. Surmodics, Inc. has a fifty-two week low of $26.00 and a fifty-two week high of $40.38.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.27. The firm had revenue of $29.57 million for the quarter, compared to analysts’ expectations of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS. On average, equities research analysts expect that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).